abstract |
The present disclosure relates generally to immunoglobulin-associated compositions (eg, antibodies or antigen binding fragments thereof) capable of binding to delta-like protein 3 (DLL3). Antibodies of the present technology are useful in methods of detecting and treating DLL3-associated cancer in a subject in need thereof. |